KLRK1 and acute myeloid leukemia: In these studies, NKG2D-CAR T cells demonstrated robust killing of AML- and T-ALL cell line targets at E:T ratios as low as 1:1, whereas no tumor cell killing was mediated by Empty control T cells (Figure 4F).